GMED logo

Globus Medical, Inc. Stock Price

NYSE:GMED Community·US$11.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 40 Fair Values set on narratives written by author

GMED Share Price Performance

US$87.17
15.87 (22.26%)
US$109.54
Fair Value
US$87.17
15.87 (22.26%)
20.4% undervalued intrinsic discount
US$109.54
Fair Value
Price US$87.17
AnalystConsensusTarget US$109.54
AnalystLowTarget US$90.00
AnalystHighTarget US$118.00

GMED Community Narratives

AnalystConsensusTarget·
Fair Value US$109.54 20.4% undervalued intrinsic discount

Spine Procedure Trends And Robotics Will Shape Industry Position Amid Margin Pressures

0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
AnalystLowTarget·
Fair Value US$90 3.1% undervalued intrinsic discount

Integration And Supply Risks Will Curb Margins Yet Unlock Value

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystHighTarget·
Fair Value US$118 26.1% undervalued intrinsic discount

Aging Demographics And Digital Trends Will Transform Orthopedic Care

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$118
26.1% undervalued intrinsic discount
Revenue
10.38% p.a.
Profit Margin
16.7%
Future PE
30.57x
Price in 2029
US$147
US$90
3.1% undervalued intrinsic discount
Revenue
6.89% p.a.
Profit Margin
15.14%
Future PE
26.98x
Price in 2029
US$112.03

Trending Discussion

Updated Narratives

GMED logo

GMED: Future Returns Will Reflect Q4 Execution And Margin Progress Potential

Fair Value: US$109.54 20.4% undervalued intrinsic discount
17 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
GMED logo

GMED: EPS Upside And Q4 2025 Revenue Outlook Will Drive Repricing

Fair Value: US$118 26.1% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
GMED logo

GMED: EPS Upside And Enabling Tech Progress Will Test Execution Through 2026

Fair Value: US$90 3.1% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with solid track record.

0 Risks
5 Rewards

Globus Medical, Inc. Key Details

US$2.9b

Revenue

US$938.3m

Cost of Revenue

US$2.0b

Gross Profit

US$1.5b

Other Expenses

US$537.9m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
3.98
68.07%
18.30%
0%
View Full Analysis

About GMED

Founded
2003
Employees
6000
CEO
Keith Pfeil
WebsiteView website
www.globusmedical.com

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Recent GMED News & Updates

Recent updates

No updates